本文選題：扶陽益氣方 + 脾腎陽虛�。� 參考：《云南中醫(yī)學院》2017年碩士論文

【摘要】：目的:通過本臨床試驗,觀察與評價扶陽益氣方治療卵巢癌化療后脾腎陽虛證的臨床療效。探討卵巢癌化療后脾腎陽虛證的治療方法和思路,為卵巢癌患者化療的順利進行及完成提供保證,以提高卵巢癌患者生存質量,延長生存期。方法:將符合本研究入組標準的病例,隨機分為2組:治療組30例和對照組30例。治療組用扶陽益氣方+參芪扶正注射液+常規(guī)治療,對照組僅予參芪扶正注射液+常規(guī)治療,兩組均治療1療程(14天/療程)。觀察對比治療前后兩組病例的中醫(yī)證候、生活質量等相關指標,進行統計學分析。結果:1.兩組患者的治療后有效率:治療組有效率86.67%,對照組有效率73.33%,治療組療效優(yōu)于對照組(P0.05)。2.脾腎陽虛癥狀積分:兩組病例治療后的中醫(yī)證候積分均較前明顯下降(P0.01),但兩者療效比較:治療組療效都明顯優(yōu)于對照組(P0.05)。3.功能狀態(tài)(KPS)評分:治療后兩組病例KPS評分較治療前均有升高,差異具有統計學意義(P0.05);治療后兩組病例的KPS評分組間比較,差異不顯著(P0.05)。4.生活質量(QOL)評分:治療后兩組病例QOL評分都較前均明顯提高(P0.01);治療后兩組病例QOL評分組間比較差異極顯著(P0.01),說明治療后QOL評分提高方面治療組明顯優(yōu)于對照組。5.療效指標:兩組患者的腫瘤標記物CA125、血常規(guī)指標均無明顯下降或升高,差異無統計學意義,其P值均0.05。兩組患者免疫指標T細胞亞群治療后較治療前均有顯著提升(P0.05),治療組明顯優(yōu)于對照組(P0.05)。6.安全指標:各組安全指標無異常波動(P0.05);未發(fā)生不良反應。結論:扶陽益氣方對卵巢癌患者化療后脾腎陽虛證有明顯的療效,并能有效改善患者的中醫(yī)臨床癥狀,提高其生活質量,該治療安全有效,無明顯毒副反應。
[Abstract]:Objective: to observe and evaluate the clinical effect of Fuyang Yiqi prescription in treating the syndrome of deficiency of spleen and kidney yang after chemotherapy of ovarian cancer.To explore the treatment methods and ideas of spleen and kidney yang deficiency syndrome after ovarian cancer chemotherapy, to provide guarantee for the smooth progress and completion of chemotherapy in ovarian cancer patients, in order to improve the quality of life and prolong the survival time of ovarian cancer patients.Methods: the patients who met the criteria were randomly divided into two groups: treatment group (n = 30) and control group (n = 30).The treatment group was treated with Fuyang Yiqi prescription Shenqi Fuzheng injection and the control group was only treated with Shenqi Fuzheng injection. Both groups were treated for 14 days / course of treatment.Observe and compare the two groups of patients before and after treatment of TCM syndrome, quality of life and other related indicators, statistical analysis.The result is 1: 1.The effective rate after treatment was 86.67 in the treatment group and 73.33 in the control group. The curative effect of the treatment group was better than that of the control group (P 0.05).The symptom integral of deficiency of spleen and kidney yang: after treatment, the TCM syndrome scores of the two groups were significantly lower than that of the former, but the curative effect of the treatment group was significantly better than that of the control group (P 0.05N. 3).After treatment, the KPS score of the two groups was higher than that before treatment, and the difference was statistically significant (P 0.05), but there was no significant difference in the KPS score between the two groups after treatment.Quality of life (QOL) score: after treatment, the QOL scores of the two groups were significantly higher than those of the former, and the difference of the QOL scores between the two groups was very significant (P 0.01), indicating that the improvement of the QOL score in the treatment group was significantly better than that in the control group (P 0.05).Curative effect index: the tumor marker CA125 and the blood routine index of the two groups were not significantly decreased or increased, and the difference was not statistically significant (P < 0.05).The immunological index of T cell subsets in both groups was significantly higher than that before treatment, and the treatment group was significantly better than the control group.Safety index: there was no abnormal fluctuation of safety index in each group (P 0.05) and no adverse reaction.Conclusion: Fuyang Yiqi prescription has obvious curative effect on the syndrome of deficiency of spleen and kidney yang after chemotherapy in patients with ovarian cancer, and can effectively improve the clinical symptoms of Chinese medicine and improve the quality of life of the patients. The treatment is safe and effective, and has no obvious side effects.
【學位授予單位】：云南中醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R273

【參考文獻】

中國期刊全文數據庫 前10條

1 莫建澍;王彬彬;沈敏鶴;;吳良村論治卵巢癌臨床經驗探析[J];浙江中醫(yī)藥大學學報;2016年09期

2 武靜蓮;徐強;謝親建;白澤明;韓金萍;李曉芳;方曉霞;;黨參抗腫瘤藥理作用研究[J];西部中醫(yī)藥;2016年08期

3 張麗;何若蘋;蔣麗;;何若蘋治療卵巢癌經驗淺析[J];浙江中醫(yī)藥大學學報;2016年07期

4 王冬梅;楊格娟;王瑩;美克熱阿依;龐瑞;;晚期卵巢癌患者中醫(yī)體質類型與中醫(yī)證型的相關性研究[J];現代中西醫(yī)結合雜志;2016年17期

5 張力文;李柳寧;何春霞;劉偉勝;;劉偉勝教授治療卵巢癌的臨床經驗[J];成都中醫(yī)藥大學學報;2016年02期

6 徐碩;姜文清;鄺詠梅;吳學軍;馬捷;金鵬飛;;茯苓的化學成分及生物活性研究進展[J];西北藥學雜志;2016年03期

7 徐先容;;黃芪桂枝五物湯加減對卵巢癌TP方案化療引起神經毒性的防治效果[J];陜西中醫(yī);2016年04期

8 樊長征;洪巧瑜;;黨參對人體各系統作用的現代藥理研究進展[J];中國醫(yī)藥導報;2016年10期

9 王守忠;高志安;;真武湯聯合紫衫醇+卡鉑(TC)方案治療卵巢癌術后患者的近期臨床效果[J];中國生化藥物雜志;2015年12期

10 蒲玉華;;腹腔鏡手術在復發(fā)性卵巢癌中的應用價值[J];實用婦產科雜志;2015年09期

中國重要會議論文全文數據庫 前1條

1 劉建文;;砂仁的藥理研究[A];新世紀全國中藥研究暨中藥房管理學術研討會論文匯編[C];2001年

中國碩士學位論文全文數據庫 前1條

1 張冬青;黃芪總黃酮及其活性成分對腫瘤細胞的抑制作用與機理研究[D];中國人民解放軍軍醫(yī)進修學院;2010年

，

本文編號：1769866